Berberine (a protoberberine isoquinoline alkaloid) has shown promising pharmacological
activities, including analgesic, anti-inflammatory, anticancer, antidiabetic, anti-hyperlipidemic, cardioprotective,
memory enhancement, antidepressant, antioxidant, anti-nociceptive, antimicrobial, anti-HIV
and cholesterol-lowering effects. It is used in the treatment of the neurodegenerative disorder. It has
strong evidence to serve as a potent phytoconstituent in the treatment of various neurodegenerative
disorders such as AD. It limits the extracellular amyloid plaques and intracellular neurofibrillary tangles.
It has also lipid-glucose lowering ability, hence can be used as a protective agent in atherosclerosis
and AD. However, more detailed investigations along with safety assessment of berberine are warranted
to clarify its role in limiting various risk factors and AD-related pathologies. This review highlights
the pharmacological basis to control oxidative stress, neuroinflammation and protective effect of
berberine in AD, which will benefit to the biological scientists in understanding and exploring the new
vistas of berberine in combating Alzheimer’s disease.